RT Journal Article
SR Electronic
T1 Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr-2017-221318
DO 10.1136/bcr-2017-221318
VO 2017
A1 Rohini J Patel
A1 Michael A Liu
A1 Akshay Amaraneni
A1 Simran K Sindhu
YR 2017
UL http://casereports.bmj.com/content/2017/bcr-2017-221318.abstract
AB Guillain-Barré syndrome is a life-threatening neurological disorder that presents with rapid ascending paralysis and areflexia. Guillain-Barré syndrome is traditionally associated with infections from a gastrointestinal or respiratory tract source. We report the case of a 71-year-old man with melanoma who was treated with ipilimumab as adjuvant immunotherapy and subsequently developed Guillain-Barré syndrome. The diagnosis was made clinically through physical exam findings. He was successfully treated with a combination of intravenous immunoglobulin therapy and corticosteroids.